Trial · NCT01162135
Digoxin for Recurrent Prostate Cancer
NCT01162135, Phase 2, Completed, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; results first posted 2014-06-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Digoxin for Recurrent Prostate Cancer. Trials, record NCT01162135. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01162135
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Digoxin for Recurrent Prostate Cancer
- NCT number
- NCT01162135
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Conditions
- Prostate Cancer
- Interventions
- Digoxin
- First posted
- 2010-07-14
- Last updated
- 2025-05-04
- Results first posted
- 2014-06-05
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Positive PSADT Outcome | 6 months after treatment with digoxin | Proportion of patients at 6 months post-treatment with a PSADT \>= 200% from baseline |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rate of Positive PSADT Outcome | 6 months after treatment with digoxin | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Positive PSADT Outcome | Digoxin | 5 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Digoxin | 16 | |
| Overall Study | COMPLETED | Digoxin | 13 | |
| Overall Study | NOT COMPLETED | Digoxin | 3 |
Source ClinicalTrials.gov
Adverse events59
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arthritis | Musculoskeletal and connective tissue disorders | Digoxin | 1 | 16 | 1 |
| other | Dizziness | General disorders | Digoxin | 2 | 16 | 2 |
| other | Change in taste | General disorders | Digoxin | 1 | 16 | 1 |
| other | Bradycardia | Cardiac disorders | Digoxin | 1 | 16 | 1 |
| other | Hyperkalemia | Blood and lymphatic system disorders | Digoxin | 2 | 16 | 4 |
| other | Hyperglycemia | Blood and lymphatic system disorders | Digoxin | 3 | 16 | 6 |
| other | Hypoglycemia | Blood and lymphatic system disorders | Digoxin | 1 | 16 | 2 |
| other | Hypophosphatemia | Blood and lymphatic system disorders | Digoxin | 1 | 16 | 1 |
| other | Incontinence | General disorders | Digoxin | 1 | 16 | 1 |
| other | Decreased appetite | General disorders | Digoxin | 2 | 16 | 3 |
1 to 10 of 59Source ClinicalTrials.gov
See all 59 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Digoxin | ||
| Total, other adverse events | Digoxin | 16 | 16 |
| Total, serious adverse events | Digoxin | 0 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01162135
GET https://conductscience.org/api/trials/v1/NCT01162135/events?page=2